The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Bacterial colonisation is an important predictor of exacerbation in AATD-COPD and may require additional targeted therapy, study suggests.

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...